

Ryo-ichi Yoshimura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2124222/publications.pdf>

Version: 2024-02-01

38
papers

500
citations

1040056

9
h-index

713466

21
g-index

39
all docs

39
docs citations

39
times ranked

834
citing authors

#	ARTICLE	IF	CITATIONS
1	Usefulness of texture features of apparent diffusion coefficient maps in predicting chemoradiotherapy response in muscle-invasive bladder cancer. <i>European Radiology</i> , 2022, 32, 671-679.	4.5	16
2	Outcomes of intensity-modulated radiation therapy for intermediate- or high-risk prostate cancer: a single-institutional study. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 170-178.	1.3	6
3	MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 124, 105666.	1.5	2
4	Impact of Progressive Site-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer on Subsequent Treatment Response. <i>Cancers</i> , 2022, 14, 567.	3.7	5
5	A Rare Case of Radiation-Induced Liver Disease in Treated Abdominal Lymphoma Showing High [18F]FDG Avidity and Low EOB Uptake Proportional to the Irradiation Dose. <i>Diagnostics</i> , 2022, 12, 504.	2.6	0
6	Focal brachytherapy for localized prostate cancer: 5.7-year clinical outcomes and a pair-matched study with radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 161.e15-161.e23.	1.6	6
7	Safety and response after peptide receptor radionuclide therapy with ¹⁷⁷ Lu- DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2022, 29, 487-499.	2.6	7
8	A custom-made brachytherapy applicator for recurrent endometrial and vaginal cancer: A dental technique for prosthesis fabrication. <i>Journal of Prosthetic Dentistry</i> , 2021, 126, 711-714.	2.8	7
9	Can progressive site-directed therapy prolong the efficacy of subsequent androgen receptor axis-targeted drugs in oligometastatic castration-resistant prostate cancer?. <i>International Journal of Urology</i> , 2021, 28, 241-242.	1.0	2
10	A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese Gynecologic Oncology Group study (JGOG1082). <i>International Journal of Gynecological Cancer</i> , 2021, 31, 623-626.	2.5	12
11	Medium-term oncological and functional outcomes of hemi-gland brachytherapy using iodine-125 seeds for intermediate-risk unilateral prostate cancer. <i>Brachytherapy</i> , 2021, 20, 842-848.	0.5	5
12	Genuine- and induced-oligometastatic castration-resistant prostate cancer: clinical features and clinical outcomes after progressive site-directed therapy. <i>International Urology and Nephrology</i> , 2021, 53, 1119-1125.	1.4	5
13	Prognostic impact of lingual lymph node metastasis in patients with squamous cell carcinoma of the tongue: a retrospective study. <i>Scientific Reports</i> , 2021, 11, 20535.	3.3	7
14	Efficacy and Safety of Induction Chemotherapy and/or External Beam Radiotherapy Followed by Brachytherapy in Patients With Tongue Cancer. <i>Anticancer Research</i> , 2021, 41, 6259-6266.	1.1	1
15	The clinical utility of comprehensive genomic profiling for recurrent / metastatic head and neck cancer. <i>Japanese Journal of Head and Neck Cancer</i> , 2021, 47, 359-365.	0.1	0
16	Inter-fractional variations in the dosimetric parameters of accelerated partial breast irradiation using a strut-adjusted volume implant. <i>Journal of Radiation Research</i> , 2020, 61, 123-133.	1.6	2
17	Outcomes after reirradiation of spinal metastasis with stereotactic body radiation therapy (SBRT): a retrospective single institutional study. <i>Journal of Radiation Research</i> , 2020, 61, 929-934.	1.6	10
18	Patterns of failure after progressive site-directed therapy in oligo-progressive castration-resistant prostate cancer. <i>International Journal of Urology</i> , 2020, 27, 634-635.	1.0	5

#	ARTICLE	IF	CITATIONS
19	Comparison of 50- and 66-Cy total irradiation doses for postoperative cervical treatment of patients with oral squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 107, 104708.	1.5	7
20	Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic Factor. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 376-381.	0.8	41
21	Outcomes of radiotherapy in advanced external auditory canal cancer. <i>Journal of Radiation Research</i> , 2019, 60, 380-386.	1.6	10
22	Intensity Modulated Radiation Therapy for Syringomatous Carcinoma of the Face: A Case Report. <i>Advances in Radiation Oncology</i> , 2019, 4, 473-477.	1.2	1
23	Treatment of oral cancers during pregnancy: a case-based discussion. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2019, 48, 9.	1.9	11
24	Promising radiotherapies: IMRT, particle therapy, brachytherapy, and BNCT. <i>Journal of Japanese Society of Oral Oncology</i> , 2019, 31, 157-173.	0.1	0
25	Clinical usefulness of 2-deoxy-2-[18F] fluoro-d-glucose-positron emission tomography/computed tomography for assessing early oral squamous cell carcinoma (cT1-2N0M0). <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 633-639.	1.3	6
26	Prognostic value of metabolic tumor burden calculated using dual-time-point 18F-fluorodeoxyglucose positron emission tomography/CT in patients with oropharyngeal or hypopharyngeal cancer. <i>Head and Neck</i> , 2018, 41, 103-109.	2.0	5
27	Impact of Immunohistochemistry-Based Subtypes in Muscle-Invasive Bladder Cancer on Response to Chemoradiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1408-1416.	0.8	17
28	Effects of dose rate on early and late complications in low dose rate brachytherapy for mobile tongue carcinoma using 192Ir sources. <i>Oral Radiology</i> , 2017, 33, 187-192.	1.9	1
29	Temporo-spatial cell-cycle kinetics in HeLa cells irradiated by Ir-192 high dose-rate remote afterloading system (HDR-RALS). <i>Radiation Oncology</i> , 2016, 11, 99.	2.7	0
30	A phase I/II clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced cervical cancer. <i>BMC Cancer</i> , 2016, 16, 640.	2.6	9
31	18F-FDG uptake of the spinal cord was decreased after conventional dose radiotherapy in esophageal cancer patients. <i>Annals of Nuclear Medicine</i> , 2016, 30, 35-39.	2.2	0
32	Repeat Brachytherapy for Patients With Residual or Recurrent Tumors of Oral Cavity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1198-1204.	0.8	5
33	Outcomes in Patients With Early-Stage Hypopharyngeal Cancer Treated With Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1017-1023.	0.8	29
34	Radiotherapy doses at special reference points correlate with the outcome of cervical cancer therapy. <i>Brachytherapy</i> , 2008, 7, 260-266.	0.5	8
35	Acute and late genitourinary toxicity of conformal radiotherapy for prostate cancer. <i>Radiation Medicine</i> , 2006, 24, 553-559.	0.8	8
36	Maintained Salivary Function after Brachytherapy in Patients with Head and Neck Carcinomas - Evaluation Using Quantitative Salivary Gland Scintigraphy. <i>Acta Oncologica</i> , 2002, 41, 684-688.	1.8	5

#	ARTICLE	IF	CITATIONS
37	Trimodal combination therapy for maxillary sinus carcinoma. International Journal of Radiation Oncology Biology Physics, 2002, 53, 656-663.	0.8	35
38	Relationship between bone marrow cellularity and apparent diffusion coefficient. Journal of Magnetic Resonance Imaging, 2001, 13, 757-760.	3.4	203